# Belite Bio, Inc (BLTE)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/belite-bio-inc/ JSON: https://steadybase.io/company/belite-bio-inc.json Checked Nov 21, 2026. Latest filing read: Nov 17, 2026.

## Company

- Legal name: BELITE BIO, INC
- Ticker: BLTE (Nasdaq)
- SEC CIK: 0001889109
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: San Diego, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: belitebio.com
- LinkedIn: https://www.linkedin.com/company/belitebio/
- Next earnings date: Feb 11, 2027

## Key facts

- Operating income: -$84.2M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/0001104659-26-037374-index.html
- Net income: -$77.6M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/0001104659-26-037374-index.html
- SG&A: $38.8M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/0001104659-26-037374-index.html
- Employees: 41 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm
- Shares outstanding: 39,339,960 as of Dec 31, 2025 (20-F filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/0001104659-26-037374-index.html
- Auditor: Deloitte & Touche, Taipei, Taiwan, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm

## Officers and directors

- Yu-Hsin Lin, Chief Executive Officer. Source: Form 4 filed Sep 9, 2026, https://www.sec.gov/Archives/edgar/data/1889109/000119312526386794/0001193125-26-386794-index.htm
- Hao-Yuan Chuang, Chief Financial Officer. LinkedIn: https://linkedin.com/in/hao-yuan-chuang-91131911. Source: Form 4 filed Sep 9, 2026, https://www.sec.gov/Archives/edgar/data/1889109/000119312526386790/0001193125-26-386790-index.htm
- Hendrik Peter Scholl, Chief Medical Officer. Source: Form 4 filed Jun 22, 2026, https://www.sec.gov/Archives/edgar/data/1889109/000119312526276615/0001193125-26-276615-index.htm
- Nathan L. Mata, Chief Scientific Officer. Source: Form 4 filed May 8, 2026, https://www.sec.gov/Archives/edgar/data/1889109/000119312526214820/0001193125-26-214820-index.htm

## Insider trades (Form 4)

- Nov 12, 2026: Hendrik Peter Scholl (Chief Medical Officer) sold 2,000 shares, about $331,976. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526464091/0001193125-26-464091-index.htm
- Oct 1, 2026: Hendrik Peter Scholl (Chief Medical Officer) sold 500 shares, about $82,659. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526414643/0001193125-26-414643-index.htm
- Sep 8, 2026: Yu-Hsin Lin (Chief Executive Officer) sold 100,435 shares, about $19.1M. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526386794/0001193125-26-386794-index.htm
- Sep 8, 2026: Hao-Yuan Chuang (Chief Financial Officer) sold 67,395 shares, about $12.8M. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526386790/0001193125-26-386790-index.htm
- Aug 12, 2026: Hao-Yuan Chuang (Chief Financial Officer) sold 367 shares, about $66,187. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526350218/0001193125-26-350218-index.htm
- Aug 12, 2026: Yu-Hsin Lin (Chief Executive Officer) sold 365 shares, about $65,827. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526350217/0001193125-26-350217-index.htm
- Jun 18, 2026: Hendrik Peter Scholl (Chief Medical Officer) sold 10,000 shares, about $1.5M. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526276615/0001193125-26-276615-index.htm
- Jun 16, 2026: Hendrik Peter Scholl (Chief Medical Officer) sold 10,000 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526273321/0001193125-26-273321-index.htm
- May 7, 2026: Nathan L. Mata (Chief Scientific Officer) sold 666 shares, about $102,038. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526214820/0001193125-26-214820-index.htm
- May 6, 2026: Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares, about $153,838. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526211974/0001193125-26-211974-index.htm
- May 5, 2026: Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares, about $155,502. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526209004/0001193125-26-209004-index.htm
- May 4, 2026: Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares, about $155,638. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526206456/0001193125-26-206456-index.htm
- May 1, 2026: Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares, about $155,779. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526204021/0001193125-26-204021-index.htm
- Apr 30, 2026: Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares, about $156,975. Source: https://www.sec.gov/Archives/edgar/data/1889109/000119312526201466/0001193125-26-201466-index.htm

## Latest filings

- 20f filed Mar 31, 2026: https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

